MX338557B - Compuesto heterociclico y uso del mismo. - Google Patents

Compuesto heterociclico y uso del mismo.

Info

Publication number
MX338557B
MX338557B MX2012014481A MX2012014481A MX338557B MX 338557 B MX338557 B MX 338557B MX 2012014481 A MX2012014481 A MX 2012014481A MX 2012014481 A MX2012014481 A MX 2012014481A MX 338557 B MX338557 B MX 338557B
Authority
MX
Mexico
Prior art keywords
heterocyclic compound
hypertension
prodrug
prophylaxis
formulas
Prior art date
Application number
MX2012014481A
Other languages
English (en)
Inventor
Takanobu Kuroita
Yasuhiro Imaeda
Kouichi Iwanaga
Naohiro Taya
Hidekazu Tokuhara
Yoshiyuki Fukase
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41282529&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX338557(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MX338557B publication Critical patent/MX338557B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Los compuestos representados a través de las fórmulas (I) (II), en donde cada símbolo es tal como se define en la especificación, y un profármaco de los mismos, tienen una actividad inhibidora de renina superior, y son útiles como agentes para la profilaxis o tratamiento de hipertensión, daños a diversos órganos atribuibles a hipertensión y similares.
MX2012014481A 2008-06-19 2010-12-09 Compuesto heterociclico y uso del mismo. MX338557B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008161049 2008-06-19
JP2009004882 2009-01-13

Publications (1)

Publication Number Publication Date
MX338557B true MX338557B (es) 2016-04-21

Family

ID=41282529

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2010013602A MX2010013602A (es) 2008-06-19 2009-06-17 Compuesto heterociclico y uso del mismo.
MX2012014481A MX338557B (es) 2008-06-19 2010-12-09 Compuesto heterociclico y uso del mismo.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2010013602A MX2010013602A (es) 2008-06-19 2009-06-17 Compuesto heterociclico y uso del mismo.

Country Status (38)

Country Link
US (5) US8466282B2 (es)
EP (1) EP2297114B1 (es)
JP (3) JP4800445B2 (es)
KR (2) KR101207830B1 (es)
CN (2) CN103373985B (es)
AR (1) AR072166A1 (es)
AU (1) AU2009261153B2 (es)
BR (1) BRPI0914802B8 (es)
CA (1) CA2728476C (es)
CL (1) CL2010001361A1 (es)
CO (1) CO6300862A2 (es)
CR (2) CR20110001A (es)
CY (1) CY1120995T1 (es)
DK (1) DK2297114T3 (es)
DO (2) DOP2010000381A (es)
EA (2) EA019755B1 (es)
EC (1) ECSP11010770A (es)
ES (1) ES2676289T3 (es)
GE (2) GEP20166443B (es)
HR (1) HRP20181370T1 (es)
HU (1) HUE039416T2 (es)
IL (1) IL209282A (es)
JO (1) JO3465B1 (es)
LT (1) LT2297114T (es)
MA (1) MA32483B1 (es)
MX (2) MX2010013602A (es)
MY (1) MY160771A (es)
NZ (2) NZ589825A (es)
PE (2) PE20140858A1 (es)
PL (1) PL2297114T3 (es)
PT (1) PT2297114T (es)
RS (1) RS57591B1 (es)
SG (1) SG188117A1 (es)
SI (1) SI2297114T1 (es)
TW (2) TWI378096B (es)
UY (1) UY31907A (es)
WO (1) WO2009154300A2 (es)
ZA (1) ZA201009073B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2202228B1 (en) 2007-10-15 2014-12-10 Takeda Pharmaceutical Company Limited Amide compounds and use of the same
CN101952280B (zh) 2007-12-19 2014-04-23 大日本住友制药株式会社 双环杂环衍生物
EP2297114B1 (en) 2008-06-19 2018-06-06 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
AU2010263641A1 (en) 2009-06-24 2012-01-19 Sumitomo Dainippon Pharma Co., Ltd. N-substituted-cyclic amino derivative
WO2011079105A1 (en) * 2009-12-23 2011-06-30 Abbott Laboratories Novel thienopyrrole compounds
ES2524896T3 (es) 2010-06-16 2014-12-15 Takeda Pharmaceutical Company Limited Cristal de compuesto de amida
EP2638035B1 (en) * 2010-11-09 2014-12-17 F.Hoffmann-La Roche Ag Triazole derivatives as ligands for Gaba receptors
US8742097B2 (en) * 2010-11-09 2014-06-03 Hoffmann-La Roche Inc. Triazole compounds I
US20120178813A1 (en) 2011-01-12 2012-07-12 Thetis Pharmaceuticals Llc Lipid-lowering antidiabetic agent
CN107879941A (zh) * 2012-02-14 2018-04-06 陶氏环球技术有限责任公司 非离子型表面活性剂组合物
US20150011549A1 (en) * 2012-02-15 2015-01-08 Takeda Pharmaceutical Company Limited Tablet
BR112014032501A2 (pt) * 2012-06-26 2017-06-27 Saniona Aps composto, e, composição farmacêutica.
US8765811B2 (en) 2012-07-10 2014-07-01 Thetis Pharmaceuticals Llc Tri-salt form of metformin
US9382187B2 (en) 2012-07-10 2016-07-05 Thetis Pharmaceuticals Llc Tri-salt form of metformin
US9878981B2 (en) 2014-04-10 2018-01-30 Takeda Pharmaceutical Company Limited Method for producing heterocyclic compound
CA2947741A1 (en) 2014-05-05 2015-11-12 Thetis Pharmaceuticals Llc Compositions and methods relating to ionic salts of peptides
US9242008B2 (en) 2014-06-18 2016-01-26 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of fatty acids
ES2706493T3 (es) 2014-06-18 2019-03-29 Thetis Pharmaceuticals Llc Complejos de aminoácidos minerales de agentes activos
US10758525B2 (en) 2015-01-22 2020-09-01 MyoKardia, Inc. 4-methylsulfonyl-substituted piperidine urea compounds
JP6906047B2 (ja) 2016-06-03 2021-07-21 テティス・ファーマシューティカルズ・エルエルシー 特異的炎症収束性メディエーターの塩に関連する組成物及び方法
CN108727249A (zh) * 2018-07-07 2018-11-02 台州学院 3-二氟甲基哌啶盐酸盐及其衍生物的合成方法

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL102183A (en) 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd The heterocyclic compounds are converted into biphenyl groups, their production and the pharmaceutical compositions containing them
RU2168510C2 (ru) 1991-07-31 2001-06-10 Такеда Кемикал Индастриз, Лтд. Гетероциклическое соединение, фармацевтическая композиция, способ антагонизирования ангиотензина ii
IL117659A (en) 1995-04-13 2000-12-06 Dainippon Pharmaceutical Co Substituted 2-phenyl pyrimidino amino acetamide derivative process for preparing the same and a pharmaceutical composition containing same
US6297269B1 (en) 1995-06-06 2001-10-02 Pfizer Inc. Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors
UA58494C2 (uk) 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
CZ132897A3 (en) 1995-09-01 1997-11-12 Lilly Co Eli Antagonist of indolylneuropeptide y receptor
TWI227240B (en) 2000-06-06 2005-02-01 Pfizer 2-aminocarbonyl-9H-purine derivatives
EP1403255A4 (en) 2001-06-12 2005-04-06 Sumitomo Pharma INHIBITORS OF RHO KINASE
US20030078278A1 (en) 2001-06-26 2003-04-24 Pfizer Inc. Spiropiperidine compounds as ligands for ORL-1 receptor
DE60235114D1 (de) 2001-11-01 2010-03-04 Icagen Inc Pyrazolamide zur anwendung in der behandlung von schmerz
JP2005518391A (ja) 2001-12-21 2005-06-23 ノボ　ノルディスク　アクティーゼルスカブ Ｇｋ活性化剤としてのアミド誘導体
DE60329990D1 (de) 2002-03-08 2009-12-24 Merck & Co Inc Mitotische kinesin-hemmer
AU2003287057B2 (en) 2002-10-18 2008-08-21 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
US20040204455A1 (en) 2003-04-10 2004-10-14 Cody Wayne Livingston Piperidine derivative rennin inhibitors
AU2004247615B2 (en) * 2003-06-18 2008-02-21 Astrazeneca Ab 2-substituted 5,6-diaryl-pyrazine derivatives as CB1 modulators
EP1664026B1 (en) 2003-08-15 2009-01-21 Merck & Co., Inc. Mitotic kinesin inhibitors
AU2004266629B2 (en) 2003-08-15 2009-11-26 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
TW200513461A (en) 2003-10-01 2005-04-16 Speedel Experimenta Ag Organische verbindungen
CA2545644C (en) 2003-11-12 2011-11-01 Lg Life Sciences Ltd. Melanocortin receptor agonists
TW200613274A (en) 2004-07-09 2006-05-01 Speedel Experimenta Ag Organic compounds
MX2007001540A (es) 2004-08-10 2007-04-23 Incyte Corp Compuestos amido y sus usos como farmaceuticos.
NZ554374A (en) 2004-10-07 2010-11-26 Vitae Pharmaceuticals Inc Diaminoalkane aspartic protease inhibitors
CA2587853A1 (en) * 2004-11-23 2006-06-01 Wyeth Gonadotropin releasing hormone receptor antagonists
GB0428526D0 (en) 2004-12-30 2005-02-09 Novartis Ag Organic compounds
CN101137372A (zh) 2005-03-16 2008-03-05 默克公司 有丝分裂驱动蛋白抑制剂
GB0511063D0 (en) 2005-05-31 2005-07-06 Novartis Ag Organic compounds
GB0514203D0 (en) * 2005-07-11 2005-08-17 Novartis Ag Organic compounds
CA2621181C (en) 2005-08-30 2011-04-19 Asahi Kasei Pharma Corporation 5-isoquinolinesulfonamide compounds
FI20055498A0 (fi) 2005-09-16 2005-09-16 Biotie Therapies Corp Sulfonamidijohdannaisia
US7618982B2 (en) 2005-12-19 2009-11-17 Nerviano Medical Sciences S.R.L. Heteroarylpyrrolopyridinones active as kinase inhibitors
KR20080086921A (ko) 2005-12-30 2008-09-26 노파르티스 아게 레닌 억제제로서의 ３,５-치환된 피페리딘 화합물
TW200804359A (en) 2006-01-19 2008-01-16 Speedel Experimenta Ag Substituted 4-phenylpiperidines
US20100121048A1 (en) 2006-02-16 2010-05-13 Takanobu Kuroita Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension
JP5067364B2 (ja) * 2006-03-24 2012-11-07 アステラス製薬株式会社 アシルアミノピペリジン化合物
GB0607954D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
US20090318430A1 (en) 2006-07-21 2009-12-24 Astex Therapeutics Limited Medical use of cyclin dependent kinases inhibitors
WO2008016666A2 (en) * 2006-08-02 2008-02-07 Cytokinetics, Incorporated Certain chemical entities, compositions, and methods
US20100056497A1 (en) * 2007-01-31 2010-03-04 Dainippon Sumitomo Pharma Co., Ltd Amide derivative
JP4837701B2 (ja) 2007-04-20 2011-12-14 田辺三菱製薬株式会社 医薬組成物
JP2010163361A (ja) * 2007-04-27 2010-07-29 Dainippon Sumitomo Pharma Co Ltd キノリン誘導体
AR066268A1 (es) 2007-04-27 2009-08-05 Takeda Pharmaceutical Compuesto de imidazol sustituido y su uso
JP2010189275A (ja) 2007-06-14 2010-09-02 Dainippon Sumitomo Pharma Co Ltd ナフタレン誘導体
TWI452044B (zh) * 2007-06-15 2014-09-11 Mitsubishi Tanabe Pharma Corp 嗎啉衍生物
WO2009001915A1 (ja) 2007-06-28 2008-12-31 Takeda Pharmaceutical Company Limited 置換イミダゾール化合物およびその用途
JP2010208947A (ja) * 2007-06-29 2010-09-24 Dainippon Sumitomo Pharma Co Ltd キノロン誘導体
JP2010229034A (ja) * 2007-07-26 2010-10-14 Dainippon Sumitomo Pharma Co Ltd 二環性ピロール誘導体
EP2202228B1 (en) 2007-10-15 2014-12-10 Takeda Pharmaceutical Company Limited Amide compounds and use of the same
JP2011037712A (ja) 2007-12-08 2011-02-24 Dainippon Sumitomo Pharma Co Ltd ４−アリールフェニル誘導体
CN101952280B (zh) 2007-12-19 2014-04-23 大日本住友制药株式会社 双环杂环衍生物
AR070454A1 (es) 2008-02-27 2010-04-07 Nycomed Gmbh Pirrolopirimidincarboxamidas y composiciones farmaceuticas que las comprenden
CA2717529A1 (en) 2008-03-11 2009-09-17 Cellzome Limited Sulfonamides as zap-70 inhibitors
JP2009298713A (ja) * 2008-06-11 2009-12-24 Daiichi Sankyo Co Ltd イミダゾチアゾール誘導体
EP2297114B1 (en) * 2008-06-19 2018-06-06 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
WO2010126002A1 (ja) 2009-04-28 2010-11-04 塩野義製薬株式会社 ヘテロ環スルホンアミド化合物を含有する医薬

Also Published As

Publication number Publication date
US20100137587A1 (en) 2010-06-03
PE20110067A1 (es) 2011-02-18
US20160046601A1 (en) 2016-02-18
DOP2013000123A (es) 2013-11-15
US8466282B2 (en) 2013-06-18
GEP20166443B (en) 2016-03-10
CA2728476C (en) 2017-03-21
TWI472523B (zh) 2015-02-11
CN102123990A (zh) 2011-07-13
KR101578264B1 (ko) 2015-12-16
US8664380B2 (en) 2014-03-04
IL209282A (en) 2015-07-30
EP2297114B1 (en) 2018-06-06
AU2009261153A1 (en) 2009-12-23
BRPI0914802B1 (pt) 2020-10-27
CN103373985B (zh) 2015-10-28
PL2297114T3 (pl) 2018-10-31
LT2297114T (lt) 2018-08-10
CL2010001361A1 (es) 2011-07-29
KR101207830B1 (ko) 2012-12-04
PE20140858A1 (es) 2014-08-04
JP2011157391A (ja) 2011-08-18
NZ589825A (en) 2012-11-30
NZ600238A (en) 2014-04-30
HRP20181370T1 (hr) 2018-10-19
CN102123990B (zh) 2014-07-09
TW201002685A (en) 2010-01-16
PT2297114T (pt) 2018-07-26
US20150191486A1 (en) 2015-07-09
US9045436B2 (en) 2015-06-02
SI2297114T1 (sl) 2018-10-30
HUE039416T2 (hu) 2018-12-28
CR20130360A (es) 2013-09-03
JP4800445B2 (ja) 2011-10-26
CA2728476A1 (en) 2009-12-23
US20120264733A1 (en) 2012-10-18
RS57591B1 (sr) 2018-11-30
JP5592831B2 (ja) 2014-09-17
SG188117A1 (en) 2013-03-28
JO3465B1 (ar) 2020-07-05
ZA201009073B (en) 2012-03-28
EA019755B1 (ru) 2014-06-30
MY160771A (en) 2017-03-15
AR072166A1 (es) 2010-08-11
US9221836B2 (en) 2015-12-29
GEP20135957B (en) 2013-11-11
CR20110001A (es) 2013-03-15
EA201170051A1 (ru) 2011-08-30
MX2010013602A (es) 2011-03-15
EP2297114A2 (en) 2011-03-23
JP2011524853A (ja) 2011-09-08
CY1120995T1 (el) 2019-12-11
BRPI0914802A2 (pt) 2015-08-11
JP5918746B2 (ja) 2016-05-18
DOP2010000381A (es) 2010-12-31
KR20120084778A (ko) 2012-07-30
WO2009154300A2 (en) 2009-12-23
EA201301040A1 (ru) 2014-01-30
KR20110019428A (ko) 2011-02-25
BRPI0914802B8 (pt) 2021-05-25
TWI378096B (en) 2012-12-01
TW201240987A (en) 2012-10-16
US20110178057A1 (en) 2011-07-21
WO2009154300A3 (en) 2010-06-03
CO6300862A2 (es) 2011-07-21
ECSP11010770A (es) 2011-02-28
IL209282A0 (en) 2011-01-31
JP2014094950A (ja) 2014-05-22
UY31907A (es) 2010-01-29
CN103373985A (zh) 2013-10-30
MA32483B1 (fr) 2011-07-03
ES2676289T3 (es) 2018-07-18
DK2297114T3 (en) 2018-07-09
AU2009261153B2 (en) 2014-05-22

Similar Documents

Publication Publication Date Title
MX338557B (es) Compuesto heterociclico y uso del mismo.
SMP201100019B (it) Composti organici
MX2010009416A (es) Compuestos heterociclicos como inhibidores de cxcr2.
TW201000473A (en) Benzene or thiophene derivative and use thereof as VAP-1 inhibitor
ATE522536T1 (de) Pyrrolopyrazin-kinasehemmer
EA201391705A1 (ru) Триазолпиридиновые ингибиторы 11-бета-гидроксистероиддегидрогеназы типа i
NO20064400L (no) Prolin-derivater, og anvendelse av samme som inhibitorer av dipeptidyl peptidase IV
MX2010008460A (es) Derivado de tiazol y su uso como inhibidor de proteina-1 de adhesion vascular.
WO2007094513A3 (en) Cyclic amine compound and use thereof for the prophylaxis or treatment of hypertension
TN2010000038A1 (en) Organic compounds
EA201290397A1 (ru) 1,3,4-оксадиазол-2-карбоксамидное соединение
MY157116A (en) Novel seh inhibitors and their use
MX2009007713A (es) Derivados de piridazina, procedimientos para su preparacion y su uso como fungicidas.
UA107784C2 (en) Inhibitor of melanin production
WO2011004162A3 (en) 1, 2, 4-thiazolidin-3-one derivatives and their use in the treatment of cancer
MX2009000420A (es) Derivados de isoindolina para el tratamiento de arritmias.
MY152061A (en) Pyrrolopyrimidinecarboxamides
MX2012000178A (es) 2-carboxamida-cicloamino-ureas utiles como inhibidores de pi3k.
MX2012000177A (es) 2-carboxamida-cicloamino-ureas sustituidas.
TN2012000034A1 (en) Methylpyrrolopyrimidinecarboxamides
TW200621727A (en) Compounds and compositions useful as cathepsin s inhibitors
TN2010000543A1 (en) Heterocylclic compound and use thereof
UA105494C2 (uk) Гетероциклічна сполука і її застосування
MX2011007641A (es) Nuevos compuestos heterociclicos como inhibidores de metap-2.